Liver health and drug safety: new study tests vorasidenib in severe cases
NCT ID NCT07250633
First seen Jan 05, 2026 · Last updated Apr 30, 2026 · Updated 18 times
Summary
This early-stage study looks at how a single dose of the drug vorasidenib is handled by the body in people with severe liver impairment versus those with normal liver function. Researchers will measure drug levels in the blood and monitor for side effects. The study involves 20 participants and includes blood tests, heart checks, and physical exams over about 77 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.